302440.KS SK bioscience Co.,Ltd.
KSCHealthcareAs of 2026-08-09 03:22
Why 302440.KS matters now
SK bioscience Co.,Ltd. (302440.KS) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩36,850.00 with +2.65% on the session and ₩2.89T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -35.15, gross margin 6.4%, and operating margin -25.3%.
Valuation
P/E (TTM)
-35.15
PEG
—
P/B
1.63
P/S
4.34
EV/EBITDA
-24.66
DCF Value
—
FCF Yield
-7.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
6.4%
Operating Margin
-25.3%
Net Margin
-12.3%
ROE
-4.5%
ROA
-2.7%
ROIC
-4.6%
Listing Info
Market
Korea
Exchange
KSC
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellflu, a cell-cultured influenza vaccine, along with its pre-filled syringe version, Skycellflu 4-ga. The company also provides pneumococcal vaccines for both adults and children, Skyzoster for shingles, and Sky Baricella, designed to prevent chickenpox in pediatric patients. Beyond its existing portfolio, SK bioscience maintains an active research and development pipeline. Several candidates have completed Phase 2 clinical trials, including an oral rotavirus vaccine, a cervical cancer vaccine, and a low-cost pneumococcal vaccine. A distinct rotavirus vaccine is currently in Phase 3 trials in Africa, while a next-generation pneumococcal vaccine is undergoing Phase 2 trials in the United States. Other projects in development include a typhoid conjugate vaccine and a COVID-19 vaccine, which is progressing through Phase 1 and Phase 1/2 clinical studies. The company was established in 2018 and is headquartered in Seongnam-si, South Korea.